http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020019752-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dffbd04747d5d9b9492e7f2ac61db6 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438 |
| filingDate | 2018-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b3c578f7916cd4a0c19923930b27200 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff0d9bb79bb873aaff69b44d842fc7b3 |
| publicationDate | 2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020019752-A |
| titleOfInvention | Chroman derivative |
| abstract | An object of the present invention is to provide a compound useful as a novel antitumor agent which targets CSC which is suggested to be importantly involved in sustained growth of malignant tumor, metastasis and recurrence of cancer and resistance to the antitumor agent. The compound represented by the formula (I) or a pharmaceutically acceptable salt thereof is provided. [Wherein, Ra represents fluorine or the like, n represents 1-4, R 1 and R 2 represent a hydrogen atom or the like, L represents a bond or the like, and V represents C 1-6 Represents an alkylene or the like, and Q represents a C 6-10 aryl or the like] [Selection diagram] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7247144-B2 |
| priorityDate | 2018-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 299.